Royalty Pharma plc
RPRX
Kedudukan dalam Saham
#892
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Harga Saham
$60.39
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$26.89B
Perubahan (1 hari)
-0.93%
Perubahan (1 tahun)
64.87%
Negara
US
Perdagangan Royalty Pharma plc (RPRX)
Kategori
Healthcare
Pendapatan untuk Royalty Pharma plc (RPRX)
Pendapatan pada Jun 2026 TTM: $1.35B
Menurut laporan kewangan terkini Royalty Pharma plc, pendapatan semasa syarikat ialah $1.35B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $1.33B, penurunan berbanding pendapatan pada tahun 2023 yang berjumlah $1.70B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Royalty Pharma plc dari 2015 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $1.35B | 1.94% |
| 2025 | $1.32B | -0.50% |
| 2024 | $1.33B | -21.72% |
| 2023 | $1.70B | 638.96% |
| 2022 | $230.06M | -81.46% |
| 2021 | $1.24B | -27.07% |
| 2020 | $1.70B | -30.85% |
| 2019 | $2.46B | 62.16% |
| 2018 | $1.52B | 13.00% |
| 2017 | $1.34B | 76.29% |
| 2016 | $761.90M | 0.42% |
| 2015 | $758.71M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | -10.73% |
HK
|
|
| $26.37M | -98.05% |
US
|
